| 7.545 -0.175 (-2.27%) | 10-09 15:44 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.07 | 1-year : | 11.68 |
| Resists | First : | 8.62 | Second : | 10 |
| Pivot price | 7.49 |
|||
| Supports | First : | 6.4 | Second : | 5.32 |
| MAs | MA(5) : | 7.48  |
MA(20) : | 7.86 |
| MA(100) : | 9.06 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 41.6 |
D(3) : | 36.5 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 11.53 | Low : | 3.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACOG ] has closed above bottom band by 47.8%. Bollinger Bands are 27.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.78 - 7.82 | 7.82 - 7.86 |
| Low: | 7.32 - 7.36 | 7.36 - 7.4 |
| Close: | 7.66 - 7.72 | 7.72 - 7.78 |
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Mon, 06 Oct 2025
Three ASCP Posters Oct 24: Alpha Cognition Presents ZUNVEYL and AChEI Clinical Insights - Stock Titan
Tue, 30 Sep 2025
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares - businesswire.com
Tue, 30 Sep 2025
Alpha Cognition stock falls after announcing public offering plan By Investing.com - Investing.com South Africa
Wed, 20 Aug 2025
Major Stock Shuffle at Alpha Cognition Inc: Directors Make Bold Moves! - TipRanks
Fri, 15 Aug 2025
300+ Nursing Homes Adopt New Alzheimer's Drug: Alpha Cognition's ZUNVEYL Shows 65% Reorder Rate - Stock Titan
Mon, 04 Aug 2025
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview - businesswire.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Financial - Conglomerates
|
|
| Shares Out | 21 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 10 (%) |
| Held by Institutions | 27.3 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 110 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.99 |
| Profit Margin | 0 % |
| Operating Margin | -346.1 % |
| Return on Assets (ttm) | -38.3 % |
| Return on Equity (ttm) | -131.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.15 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -0.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -4.69 |
| PEG Ratio | 0 |
| Price to Book value | 3.74 |
| Price to Sales | 33.92 |
| Price to Cash Flow | -12.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|